Aggressive generic delay practices are troubling because, unlike patent exclusivity, they do not promote any public interest Increasing the costs of drugs has emerged as a core strategy for pharmaceutical…
Posts published in October 2017
Many factors influence whether physicians prescribe brand name or generic drugs High prices for prescription drugs are the focus of several bills that are currently working their way through Congress, including bills…
Pharmaceutical companies have devised powerful strategies to forestall their loss of profits post patent expiration Losing patent protection on a drug is the only certainty in the constantly changing world…
Identifying the testing phase can be tricky This is a guest post from Nicole Stakleff and Kyle Dolinsky in Pepper Hamilton’s Health Sciences Department. Nicole can be contacted at stakleffn@pepperlaw.com. Calculating…
Companies developing a new drug product, even if it is not an NCE, should explore ways to increase the likelihood of obtaining and maximizing PTE This is a guest post…
The value of obtaining multiple PTEs on different patents could incentivize innovators to revise their clinical development programs This is a guest post from Nicole Stakleff and Kyle Dolinsky in…
The total cost of developing, manufacturing, testing, and marketing a generic drug in India costs just 20% to 40% of the expenses in the West. A Glimpse of the API…
Billions are on the table for those who can break out of the mind rubble This is a guest post from John G. Singer. John is Director, Global Healthcare Strategy,…
The financial risks of being found liable for patent infringement are astronomically high Developing a strategy for the development, production and the final launch of a new drug is a…
There is a strong incentive to find out new opportunities for the discovery of new drugs Annual sales in the pharmaceutical sector have been increasing in the double-digit range for…